Targeting hexokinase 2 to induce breast cancer cell senescence

Area of Science:

• Biochemistry
• Cancer Biology
• Metabolic Regulation

Background:

• Hexokinase 2 (HK2) is a key enzyme in tumor cell proliferation and a target for anti-cancer drugs like 3-bromopyruvic acid (3-BP).
• Standard chemotherapy can induce cancer cell senescence, leading to metabolic reprogramming and treatment failure.
• The role of HK2 in chemotherapy-induced senescence and its metabolic implications remain unclear.

Purpose of the Study:

• To investigate if targeting HK2 can induce cancer cell senescence.
• To determine if metabolic changes in senescent cancer cells are linked to their HK2 status.
• To explore the HK2/HK1 ratio as a potential marker for cancer cell senescence.

Main Methods:

• Assessed HK1 and HK2 expression using immunoblot and immunofluorescence in cell lines and murine breast cancer (BC) cells.
• Evaluated the senescence-inducing potential of HK2 inhibition.
• Analyzed the effect of chemotherapy-induced senescence on HK1 and HK2 expression.
• Utilized single-cell RNA sequencing data from BC patients to confirm findings.

Main Results:

• BC cell sensitivity to HK2 inhibition did not correlate with HK2 expression levels.
• Cellular senescence was associated with decreased HK2 and increased HK1 expression.
• Genetic knockdown of HK2 induced senescence, indicating that a shift in the HK2/HK1 ratio drives senescence.
• This HK2/HK1 ratio shift was confirmed in patient BC biopsy data.

Conclusions:

• The HK2/HK1 ratio shift may serve as a novel biomarker for BC cell senescence.
• Targeting HK2 is promising for untreated cancers.
• Senescence-inducing therapies might reduce the efficacy of HK2-targeted treatments in pre-treated patients.